Cargando…
Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
BACKGROUND: Release of neutrophil extracellular traps (NETs) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) is associated with periprocedural myocardial infarction, as a result of microvascular obstruction via pro‐inflammatory and prothrombotic pathways. Colchicine i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955504/ https://www.ncbi.nlm.nih.gov/pubmed/33346683 http://dx.doi.org/10.1161/JAHA.120.018993 |
_version_ | 1783664266981670912 |
---|---|
author | Vaidya, Kaivan Tucker, Bradley Kurup, Rahul Khandkar, Chinmay Pandzic, Elvis Barraclough, Jennifer Machet, Joshua Misra, Ashish Kavurma, Mary Martinez, Gonzalo Rye, Kerry‐Anne Cochran, Blake J. Patel, Sanjay |
author_facet | Vaidya, Kaivan Tucker, Bradley Kurup, Rahul Khandkar, Chinmay Pandzic, Elvis Barraclough, Jennifer Machet, Joshua Misra, Ashish Kavurma, Mary Martinez, Gonzalo Rye, Kerry‐Anne Cochran, Blake J. Patel, Sanjay |
author_sort | Vaidya, Kaivan |
collection | PubMed |
description | BACKGROUND: Release of neutrophil extracellular traps (NETs) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) is associated with periprocedural myocardial infarction, as a result of microvascular obstruction via pro‐inflammatory and prothrombotic pathways. Colchicine is a well‐established anti‐inflammatory agent with growing evidence to support use in patients with coronary disease. However, its effects on post‐PCI NET formation in ACS have not been explored. METHODS AND RESULTS: Sixty patients (40 ACS; 20 stable angina pectoris) were prospectively recruited and allocated to colchicine or no treatment. Within 24 hours of treatment, serial coronary sinus blood samples were collected during PCI. Isolated neutrophils from 10 patients with ACS post‐PCI and 4 healthy controls were treated in vitro with colchicine (25 nmol/L) and stimulated with either ionomycin (5 μmol/L) or phorbol 12‐myristate 13‐acetate (50 nmol/L). Extracellular DNA was quantified using Sytox Green and fixed cells were stained with Hoechst 3342 and anti‐alpha tubulin. Baseline characteristics were similar across both treatment and control arms. Patients with ACS had higher NET release versus patients with stable angina pectoris (P<0.001), which was reduced with colchicine treatment (area under the curve: 0.58 versus 4.29; P<0.001). In vitro, colchicine suppressed unstimulated (P<0.001), phorbol 12‐myristate 13‐acetate–induced (P=0.009) and ionomycin‐induced (P=0.002) NET formation in neutrophils isolated from patients with ACS post‐PCI, but not healthy controls. Tubulin organization was impaired in neutrophils from patients with ACS but was restored by colchicine treatment. CONCLUSIONS: Colchicine suppresses NET formation in patients with ACS post‐PCI by restoring cytoskeletal dynamics. These findings warrant further investigation in randomized trials powered for clinical end points. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12619001231134. |
format | Online Article Text |
id | pubmed-7955504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79555042021-03-17 Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention Vaidya, Kaivan Tucker, Bradley Kurup, Rahul Khandkar, Chinmay Pandzic, Elvis Barraclough, Jennifer Machet, Joshua Misra, Ashish Kavurma, Mary Martinez, Gonzalo Rye, Kerry‐Anne Cochran, Blake J. Patel, Sanjay J Am Heart Assoc Original Research BACKGROUND: Release of neutrophil extracellular traps (NETs) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) is associated with periprocedural myocardial infarction, as a result of microvascular obstruction via pro‐inflammatory and prothrombotic pathways. Colchicine is a well‐established anti‐inflammatory agent with growing evidence to support use in patients with coronary disease. However, its effects on post‐PCI NET formation in ACS have not been explored. METHODS AND RESULTS: Sixty patients (40 ACS; 20 stable angina pectoris) were prospectively recruited and allocated to colchicine or no treatment. Within 24 hours of treatment, serial coronary sinus blood samples were collected during PCI. Isolated neutrophils from 10 patients with ACS post‐PCI and 4 healthy controls were treated in vitro with colchicine (25 nmol/L) and stimulated with either ionomycin (5 μmol/L) or phorbol 12‐myristate 13‐acetate (50 nmol/L). Extracellular DNA was quantified using Sytox Green and fixed cells were stained with Hoechst 3342 and anti‐alpha tubulin. Baseline characteristics were similar across both treatment and control arms. Patients with ACS had higher NET release versus patients with stable angina pectoris (P<0.001), which was reduced with colchicine treatment (area under the curve: 0.58 versus 4.29; P<0.001). In vitro, colchicine suppressed unstimulated (P<0.001), phorbol 12‐myristate 13‐acetate–induced (P=0.009) and ionomycin‐induced (P=0.002) NET formation in neutrophils isolated from patients with ACS post‐PCI, but not healthy controls. Tubulin organization was impaired in neutrophils from patients with ACS but was restored by colchicine treatment. CONCLUSIONS: Colchicine suppresses NET formation in patients with ACS post‐PCI by restoring cytoskeletal dynamics. These findings warrant further investigation in randomized trials powered for clinical end points. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12619001231134. John Wiley and Sons Inc. 2020-12-21 /pmc/articles/PMC7955504/ /pubmed/33346683 http://dx.doi.org/10.1161/JAHA.120.018993 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Vaidya, Kaivan Tucker, Bradley Kurup, Rahul Khandkar, Chinmay Pandzic, Elvis Barraclough, Jennifer Machet, Joshua Misra, Ashish Kavurma, Mary Martinez, Gonzalo Rye, Kerry‐Anne Cochran, Blake J. Patel, Sanjay Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention |
title | Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention |
title_full | Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention |
title_fullStr | Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention |
title_full_unstemmed | Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention |
title_short | Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention |
title_sort | colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955504/ https://www.ncbi.nlm.nih.gov/pubmed/33346683 http://dx.doi.org/10.1161/JAHA.120.018993 |
work_keys_str_mv | AT vaidyakaivan colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT tuckerbradley colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT kuruprahul colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT khandkarchinmay colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT pandzicelvis colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT barracloughjennifer colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT machetjoshua colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT misraashish colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT kavurmamary colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT martinezgonzalo colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT ryekerryanne colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT cochranblakej colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention AT patelsanjay colchicineinhibitsneutrophilextracellulartrapformationinpatientswithacutecoronarysyndromeafterpercutaneouscoronaryintervention |